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Abstract 
Hyperprolactinaemia is often found in patients with schizophrenia and usually 
considered a consequence of antipsychotics. Prolactin levels were measured 
in 43 At-Risk Mental State individuals (ARMS) and 26 patients with First 
Episode Psychosis (FEP).  Hyperprolactinaemia was found in 25.6% of ARMS 
and 46.2% of FEP. Within 60 antipsychotic-naïve ARMS and FEP, 
hyperprolactinaemia was found in 26.7%. Hyperprolactinaemia may be pre-
existing in a subgroup of patients with schizophrenia. 
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1 Introduction 
Hyperprolactinaemia has often been found in patients with chronic 
schizophrenia. It can be an adverse effect of conventional, but also many 
atypical antipsychotics (Bushe and Shaw, 2007; Kinon et al., 2003), for 
reviews see (Bushe et al., 2008; Montejo, 2008; Riecher-Rössler et al., 2009) 
and seems to be related mainly to the D2-receptor affinity of antipsychotics 
(Montejo, 2008). 
Hyperprolactinaemia can have many adverse clinical effects (Riecher-Rössler 
et al., 2009). It can not only lead to galactorrhoea, but also suppresses the 
activity of the hypothalamic-pituitary-gonadal (HPG) axis and thereby gonadal 
function, leading to reduced physiological production of estrogens and 
testosterone (Dickson et al., 2000). This can cause amenorrhoea and 
menstrual irregularities in women and erectile dysfunction, ejaculatory 
problems and reduced spermatogenesis in men. In both genders it can be 
associated with loss of libido, orgasmic dysfunction, infertility and emotional 
lability  (Haddad and Wieck, 2004; Miller, 2004). When chronic, it can cause 
osteopenia and osteoporosis (O'Keane and Meaney, 2005) and increase the 
risk of bone fractures (Howard et al., 2007).  
However, there are indications that hyperprolactinaemia in schizophrenic 
patients might, in some cases, not be due to antipsychotics but a pre-existing 
condition. Hypoestrogenaemia in women with schizophrenia has been 
described long before the introduction of antipsychotics (Diczfalusy and 
Lauritzen, 1961; Riecher-Rössler and Häfner, 1993). This has been 
hypothesized to be a consequence of stress-induced hyperprolactinaemia 
(Riecher-Rössler and Häfner, 1993). Unfortunately, prolactin was not 
examined in those patients and there are few recent studies on prolactin levels 
in antipsychotic-free or -naïve patients with schizophrenia, with contradictory 
results showing increases, decreases or comparable concentrations in 
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schizophrenic compared to healthy subjects (Kahn et al., 2008; Meltzer, 1987; 
Segal et al., 2004). 
In individuals with an At-Risk Mental State for psychosis (ARMS), to our 
knowledge prolactin levels have not been investigated up to now. We 
therefore performed a small study on prolactin levels in ARMS individuals and 
FEP patients, most of whom were antipsychotic-naïve.  
We hypothesized that hyperprolactinaemia can occur in neuroleptic-naïve FEP 
patients, and even in ARMS individuals.  
 
 
2 Materials and Methods  
Subjects were recruited in the context of the FEPSY study, a prospective 
study on the early recognition of psychosis (FrühErkennung von PSYchosen) 
at the University Psychiatric Outpatient Department, Basel. The inclusion and 
exclusion criteria have been described in detail elsewhere (Riecher-Rössler et 
al., 2007). Briefly, the Basel Screening Instrument for Psychosis (BSIP) was 
used to identify ARMS, corresponding to the criteria described by Yung et al. 
(1998). 
Exclusion criteria were age <18, insufficient knowledge of German, IQ <70, 
psychosis clearly due to organic brain disease or substance abuse (except 
cannabis).  
 
2.1 Subjects 
Subjects were recruited from 03/01/2000 to 02/29/2004, 234 individuals were 
screened in our specialised clinic. For details see Riecher-Rössler et al. 
(2007). Prolactin measurements could be obtained from 43 ARMS and 26 
FEP.  
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Subjects were interviewed in detail about any antipsychotics they had ever 
taken in the past (lifetime) and about all medication they were taking at the 
time of blood sampling. Also, medical records were taken into account, 
especially concerning the precise date any neuroleptic medication was 
initiated. All psychotropic medication was categorised into three groups: high-
potency neuroleptics, antidepressants and tranquilizers (see Table 1). 
The study was approved by the Ethics Committee of Basel, Switzerland, and 
all individuals included in the study gave written informed consent. 
 
2.2 Prolactin measurement 
The Elecsys Prolactin assay, an electrochemiluminescence immunoassay, 
Ref Number 03203093 190, Roche Diagnostics GmbH D-68298 Mannheim, 
was used to measure prolactin levels. The method has been standardized 
against the 3rd IRP WHO Reference Standard 84/500. The lower and upper 
reference limits were calculated as the 5th and 95th percentiles. 
Hyperprolactinaemia was defined as a prolactin level above the 95th 
percentile. 
 
3 Results 
Table 1 shows the socio-demographic characteristics of the individuals, their 
medication, and prolactin values. 
Insert Table 1  
Hyperprolactinemia was found in 11 (25.6%) of 43 ARMS, one of the 11 had 
been taking low dose olanzapine for behavioural control for 1.5 months, the 
other 10 were antipsychotic-naïve at the time the blood sample was taken. 
Amongst FEP patients, hyperprolactinaemia was found in 46.2% (12/26). Half 
of those (6/12) were antipsychotic-naïve, the others had been taking low-dose 
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olanzapine or risperidone for less than 3 months.  Thus, 10 of the 
neuroleoptic-naïve ARMS (23.8 %) and 6 of the neuroleptic-naïve FEP (33.3 
%) had hyperprolactinaemia. 
Figure 1 shows the prolactin serum values of the neuroleptic-naïve patients.  
Insert Figure 1 
 
4 Discussion 
In this study we found hyperprolactinaemia in about 20% of the neuroleptic-
naïve ARMS individuals and in about 30% of the neuroleptic-naïve FEP 
patients.  
Our findings indicate that hyperprolactinaemia in schizophrenia is not 
necessarily only caused by antipsychotic treatment, but might already be 
present in neuroleptic-naïve FEP and even in prodromal stages. There was a 
gender effect with mean prolactin values elevated only in female ARMS and 
FEP. 
In this context it is interesting to note that hypoestrogenaemia and irregular 
menstrual cycles, the main consequences of hyperprolactinaemia, have also 
been described in many unmedicated schizophrenia patients (Riecher-
Rössler, 2005; Riecher-Rössler et al., 1998; Häfner and Riecher-Rössler 
1993). This could well be due to previously often undiagnosed 
hyperprolactinaemia, as prolactin can suppress gonadal function and 
physiological estrogen production. Early clinicians such as Kraepelin (1909) or 
Kretschmer (1921) reported that many schizophrenic women showed physical 
signs indicating “insufficient functioning of the sexual glands” with 
“hypoestrogenism”. In the 1930s, studies analysing estrogen levels in blood 
and urine confirmed these observations. Researchers found decreased 
estrogen blood levels in most of the schizophrenic inpatients they examined  
(Diczfalusy and Lauritzen, 1961). As at the time neuroleptic therapy had not 
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been introduced, the observed abnormalities cannot be interpreted as side 
effects of neuroleptics. Prolactin levels, unfortunately, were not measured in 
those days. 
Segal et al. (2004) and also Mazure et al. (1997) found prolactin levels within 
or close to the normal range in unmedicated patients with schizophrenia.  
However, just recently in the EUFEST study, investigating 498 FEP patients, 
hyperprolactinaemia was found in 71% of FEP, most of whom were 
neuroleptic-free (Kahn et al., 2008). 
Our finding of hyperprolactinemia could be caused by general stress 
associated with the illness experience, as stress can induce 
hyperprolactinaemia (Biondi and Picardi, 1999).  
There also is evidence for increased pituitary volume in antipsychotic-free FEP 
patients (Garner et al., 2005; Pariante et al., 2005). This could indicate an 
increased pituitary activity associated with prolactin production (MacMaster et 
al., 2007). Recently, Mondelli et al. (2008) found enlarged pituitary volumes 
even in unaffected relatives of patients with schizophrenia.  
Dopaminergic transmission is well known to be increased in psychosis. We 
also know that dopamine is the most important prolactin inhibiting factor. The 
reciprocal relationship between prolactin and hypothalamic dopamine 
secretion has been confirmed in many studies (Grattan and Kokay, 2008). 
Thus it could well be that stress induces hyperprolactinaemia and that the 
increase of dopamine in psychosis is – at least partly - a regulatory 
mechanism in order to down-regulate prolactin.  
A limitation of our study is the small sample size and results need to be 
confirmed in larger samples before definite conclusions can be drawn. 
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5 Conclusions 
 
Our findings support that prolactin should be measured in FEP patients before 
introducing antipsychotics. If serum prolactin levels are already increased, 
clinicians should consider choosing prolactin sparing neuroleptics. 
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Table 1 
 
Sample characteristics and prolactin valuesa 
 
 FEPb ARMSc p 
n (men / women) 26 (19 / 7) 43 (23 / 20) χ2=0.203, p=0.653 
mean age (± SD) 30.5 (7.4) 25.7 (7.6) U-Test=344.5, p=0.008 
n patients on high-potency 
neuroleptics (%) 
7 (28.0) 1 (2.3) χ2=9.564, p=.002 
n patients on antidepressants  
(%) 
4 (16.0) 9 (20.9) χ2=0.249, p=.618 
n patients on 
tranquilisers (%) 
12  (48.0) 9 (20.9) χ2=5.427, p=0.02 
 
Prolactin values d,e 
 
men: prolactin mean (± SD) 18.3 (11.8) 13.5 (8.2) U-Test =164.5, p=0.172 
 
men: prolactin median men3 16.0 12.2  
 
women: prolactin mean 
(± SD) 
157.1 (333.2) 30.55(34.9) U-Test =42.0, p=0.13 
women: prolactin median 31.4 21.8  
 
Prolactin values in the subgroup of antipsychotic-naive patients d,e 
 
n (men/women) 13/5 23/19  
men: prolactin mean (± SD) 
 
16.5 (11.8) 13.5 (8.2) U-Test =124.5, p=0.415 
men: prolactin median 15.9 12.2  
women: prolactin mean 
(± SD) 
26.9 (14.1) 30.6 (35.9) U-Test =37.0, p=0.489 
women: prolactin median 
 
24.1 21.7  
 
a
 Prolactin serum levels are given in µg/l   
b
 FEP: First Episode Psychosis; one missing for medication at time of blood test 
c ARMS: Individuals with an At-Risk Mental State 
d
 Reference prolactin serum level, men: 4.1–18.4 µg/l 
e
 Reference prolactin serum level, women: 3.4–24.1 µg/l 
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Supplementary Table 2: Patients with hyperprolactinaemia - prolactin values at 
the time of blood sample 
 
(*) with potential effect on prolactin levels 
1. ARMS    
 
Prolactin 
value 
µg/l 
High-potency neuroleptic 
treatment (duration) 
Other 
psychotropic 
medication (*) 
male 20.9 none none 
male 23 none none 
female 24.9 none none 
female 41 none none 
male 44.3 none none 
female 46.2 none none 
female 54.7 none none 
female 166 none none 
female 48.8 none chlorprothixen 
male 19 none chlorprothixen 
female 29 olanzapine (1.5 months) paroxetine 
2. FEP    
male 22.2 none none 
female 31.4 none none 
male 46.8 none none 
male 21.1 none none 
female 47.5 none chlorprothixen 
male 29.6 none chlorprothixen 
male 25 olanzapine (2 days) chlorprothixen 
male 26 olanzapine (3 months) 
venlafaxine, 
chlorprothixen 
female 912 olanzapine (1 month) missing 
male 39.3 risperidone (2 days) none 
female 53.5 risperidone (1 day) none 
male 26.8 risperidone (missing) fluoxetine 
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Fig. 1. Prolactin serum levels in neuroleptic-naïve patients according to group and 
gender. Reference prolactin serum levels: men 4.1-18.4 µg/l, women 3.4-24.1 µg/l. 
One outlier (*) in the male ARMS group.  
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